Sorry, you need to enable JavaScript to visit this website.

What Is SYMTUZA® | SYMTUZA® (darunavir/cobicistat/emtricitabine/tenofovir alafenamide)

What is SYMTUZA®?

Once-daily SYMTUZA® is a complete prescription HIV treatment regimen in one pill. It can be taken by adults and children who weigh at least 88 pounds (40 kg) who have never received HIV medicines in the past, or whose healthcare providers have determined that they meet certain requirements.

SYMTUZA® contains 800 mg darunavir/150 mg cobicistat/200 mg emtricitabine/10 mg tenofovir alafenamide. It is not known if SYMTUZA® is safe and effective in children weighing less than 88 pounds (40 kg).

Considering SYMTUZA®

"It was important to start my
treatment right away."

-Brandon, SYMTUZA® Patient

Rapid Initiation with SYMTUZA®.

After an HIV diagnosis, your doctor may recommend starting treatment right away, and before you get the results of your lab tests. This is called rapid initiation and has several key benefits.

What is rapid initiation?

Ready to be treated?

If you were just diagnosed with HIV, talk to your healthcare provider about getting treated immediately with SYMTUZA®.

If you’re considering switching treatment, ask your doctor about SYMTUZA®.

Stay undetectable.

If you’re currently undetectable, you could stay that way while switching. In a clinical trial, 95% of patients who switched to SYMTUZA® stayed undetectable (viral load <50 copies/mL) after 48 weeks.

1% of patients didn’t stay undetectable (viral load >50 copies/mL), and among patients in the study who didn’t switch to SYMTUZA®, 94% stayed undetectable versus 1% who did not.

The study looked at 1,141 patients who were already being treated for HIV and were undetectable (<50 copies/mL) for at least 6 months. At the start of the trial, 763 patients switched to SYMTUZA®, while the remaining 378 continued their previously prescribed treatment. The final measure of the study was to see the number of patients who remained undetectable (viral load <50 copies/mL) after 48 weeks after switching to SYMTUZA®.

Side effects.

1% of patients stopped taking SYMTUZA® due to side effects compared to 1% of patients who stopped due to side effects while on their current treatment.

The most common drug-related side effects occurring in at least 2% of patients taking SYMTUZA® were diarrhea and bone weakness. These are not the only side effects of SYMTUZA®.

High resistance barrier and darunavir.

Forgetting a dose of medication can give HIV an opportunity to mutate or “outsmart” your medication, making it no longer work effectively. This is called drug resistance.

SYMTUZA® has an ingredient called darunavir, which can help reduce your risk of drug resistance. See why treatment with darunavir may be a good choice.

Do not miss a dose of SYMTUZA®. When your SYMTUZA® supply starts to run low, get more from your healthcare provider or pharmacy. This is very important because the amount of virus in your blood may increase if the medicine is stopped for even a short time. The virus may develop resistance to SYMTUZA® and become harder to treat.


Clinically tested.

SYMTUZA® has been tested in clinical studies with people just starting treatment and those who switched.

Learn more